Brokerages expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to announce earnings per share (EPS) of ($0.70) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with estimates ranging from ($0.94) to ($0.41). AMAG Pharmaceuticals posted earnings of ($0.77) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 9.1%. The firm is expected to report its next quarterly earnings report on Thursday, November 7th.
On average, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($3.03) per share for the current financial year, with EPS estimates ranging from ($3.54) to ($2.58). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.80) per share, with EPS estimates ranging from ($3.27) to ($1.13). Zacks’ earnings per share averages are an average based on a survey of research firms that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.62). The company had revenue of $78.00 million during the quarter, compared to analyst estimates of $90.72 million. AMAG Pharmaceuticals had a negative net margin of 64.33% and a negative return on equity of 31.31%. The company’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS.
Several research firms have recently commented on AMAG. Zacks Investment Research raised AMAG Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $9.25 price objective for the company in a report on Thursday, June 20th. Cowen reaffirmed a “hold” rating and set a $13.00 price target on shares of AMAG Pharmaceuticals in a report on Monday, June 24th. BidaskClub downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $9.00 price target on shares of AMAG Pharmaceuticals in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $15.53.
In other news, major shareholder Armistice Capital, Llc acquired 259,016 shares of the stock in a transaction on Tuesday, June 25th. The shares were purchased at an average price of $8.59 per share, for a total transaction of $2,224,947.44. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Julie Krop acquired 10,000 shares of the stock in a transaction on Tuesday, May 28th. The shares were purchased at an average price of $9.91 per share, for a total transaction of $99,100.00. Following the transaction, the insider now directly owns 81,399 shares in the company, valued at $806,664.09. The disclosure for this purchase can be found here. Insiders have acquired a total of 958,016 shares of company stock valued at $7,676,077 in the last ninety days. Insiders own 4.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Camber Capital Management LP increased its position in shares of AMAG Pharmaceuticals by 13.2% in the second quarter. Camber Capital Management LP now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $29,970,000 after purchasing an additional 350,000 shares during the period. Renaissance Technologies LLC increased its position in shares of AMAG Pharmaceuticals by 4.5% in the second quarter. Renaissance Technologies LLC now owns 2,034,200 shares of the specialty pharmaceutical company’s stock worth $20,322,000 after purchasing an additional 87,500 shares during the period. Robeco Institutional Asset Management B.V. increased its position in shares of AMAG Pharmaceuticals by 6.4% in the first quarter. Robeco Institutional Asset Management B.V. now owns 1,304,639 shares of the specialty pharmaceutical company’s stock worth $16,803,000 after purchasing an additional 79,007 shares during the period. Acadian Asset Management LLC increased its position in shares of AMAG Pharmaceuticals by 34.7% in the second quarter. Acadian Asset Management LLC now owns 919,064 shares of the specialty pharmaceutical company’s stock worth $9,180,000 after purchasing an additional 236,984 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of AMAG Pharmaceuticals by 12.4% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 790,424 shares of the specialty pharmaceutical company’s stock worth $7,896,000 after purchasing an additional 87,336 shares during the period.
Shares of NASDAQ AMAG traded down $0.26 during trading hours on Friday, hitting $10.03. The company had a trading volume of 565,806 shares, compared to its average volume of 1,857,908. The stock has a market capitalization of $347.46 million, a P/E ratio of -2.59 and a beta of 0.43. The company has a quick ratio of 1.50, a current ratio of 1.60 and a debt-to-equity ratio of 0.55. AMAG Pharmaceuticals has a 1-year low of $6.81 and a 1-year high of $25.20. The firm’s 50 day moving average is $9.55 and its 200-day moving average is $11.41.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Article: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.